RxDoctor Payments Data

William Korman, MD

Family Medicine · Lexington, SCNPI 1740298066

Payments from drug & device makers

$8,210in general payments, 2019–2025

Across 482 payments — averaging $17.03 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$992
  • AbbVie$652
  • Novo Nordisk$629
  • Lilly USA, LLC$576
  • Pfizer$572
  • Supernus Pharmaceuticals, Inc.$505
  • plus $4K from 47 others

What the payments were for

  • Food & beverage$8,09899%
  • Education$1121%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,210 in reported general payments places this provider in the 90th percentile of 2,153 family medicine providers in South Carolina.

See all family medicine providers in South Carolina

Medicare billing

Part B allowed, 2024
$221,906
Medicare patients
482
Services billed
11,217

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide124$172,832
JanuviaSitagliptin Phosphate105$102,453
MounjaroTirzepatide74$100,765
JardianceEmpagliflozin99$94,278
FarxigaDapagliflozin Propanediol62$73,061
EliquisApixaban59$52,469
TrulicityDulaglutide41$46,907
MyrbetriqMirabegron45$36,090
Humalog Kwikpen U-200Insulin Lispro38$35,414
Lantus SolostarInsulin Glargine,hum.Rec.Anlog146$22,291
VascepaIcosapent Ethyl14$10,509
SynthroidLevothyroxine Sodium113$8,563
Rosuvastatin Calcium453$7,824
Novolog FlexpenInsulin Aspart27$6,715
Mirabegron ErMirabegron15$6,033

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$629$172,832124 claims
Lilly USA, LLCMounjaro, Trulicity$576$147,672115 claims
MerckJanuvia$73$102,453105 claims
Boehringer IngelheimJardiance$167$94,27899 claims
AstraZenecaFarxiga$992$73,06162 claims
PfizerEliquis$572$52,46959 claims
Astellas Pharma US IncMyrbetriq$405$36,09045 claims
AbbVieSynthroid$652$8,563113 claims
GSKArexvy$201$3,46414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,153 family medicine providers in South Carolina.

Other family medicine in Lexington

See the full list for South Carolina

Where these figures come from

Is this you, or does something look wrong? →